[
  {
    "ts": "2025-12-17T22:07:54+00:00",
    "headline": "Amgen (AMGN) Valuation Check After FDA Expansion of UPLIZNA in Generalized Myasthenia Gravis",
    "summary": "Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized myasthenia gravis, expanding both the drug’s addressable market and the company’s autoimmune footprint. See our latest analysis for Amgen. The UPLIZNA approval lands at a time when momentum in Amgen’s stock is quietly building, with the recent autoimmune wins, orphan drug progress and a dividend hike helping underpin an 18.94% 3 month share price return and a 5 year total...",
    "url": "https://finance.yahoo.com/news/amgen-amgn-valuation-check-fda-220754058.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "19ffb523-dddf-3f31-962f-ecd658de1333",
      "content": {
        "id": "19ffb523-dddf-3f31-962f-ecd658de1333",
        "contentType": "STORY",
        "title": "Amgen (AMGN) Valuation Check After FDA Expansion of UPLIZNA in Generalized Myasthenia Gravis",
        "description": "",
        "summary": "Amgen (AMGN) just picked up a meaningful FDA win, with UPLIZNA cleared for a specific subset of adults with generalized myasthenia gravis, expanding both the drug’s addressable market and the company’s autoimmune footprint. See our latest analysis for Amgen. The UPLIZNA approval lands at a time when momentum in Amgen’s stock is quietly building, with the recent autoimmune wins, orphan drug progress and a dividend hike helping underpin an 18.94% 3 month share price return and a 5 year total...",
        "pubDate": "2025-12-17T22:07:54Z",
        "displayTime": "2025-12-17T22:07:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-valuation-check-fda-220754058.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-valuation-check-fda-220754058.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T19:16:04+00:00",
    "headline": "HSBC Turns More Bullish on Amgen (AMGN) into 2026",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]",
    "url": "https://finance.yahoo.com/news/hsbc-turns-more-bullish-amgen-191604682.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f5230dd6-436e-3e93-86de-97c79964efdb",
      "content": {
        "id": "f5230dd6-436e-3e93-86de-97c79964efdb",
        "contentType": "STORY",
        "title": "HSBC Turns More Bullish on Amgen (AMGN) into 2026",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 12 Best Dogs of the Dow to Invest in. On December 8, HSBC lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $425 from $381. The firm also retained a Buy rating. The call came as part of the firm’s 2026 outlook for the pharma sector. HSBC sees […]",
        "pubDate": "2025-12-17T19:16:04Z",
        "displayTime": "2025-12-17T19:16:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "HSBC Turns More Bullish on Amgen (AMGN) into 2026",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fl9k_iPg0JyfVI.qZJRd8A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RgojEqpZ8ITlaPGpQimL8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/51e557354b24b248245adac46ac0da45.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hsbc-turns-more-bullish-amgen-191604682.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hsbc-turns-more-bullish-amgen-191604682.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "HSBC"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-17T14:00:03+00:00",
    "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/investors-heavily-search-amgen-inc-140003182.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "7f350892-3c81-3ac9-887a-d219cd068320",
      "content": {
        "id": "7f350892-3c81-3ac9-887a-d219cd068320",
        "contentType": "STORY",
        "title": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know",
        "description": "",
        "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2025-12-17T14:00:03Z",
        "displayTime": "2025-12-17T14:00:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2",
          "originalWidth": 900,
          "originalHeight": 625,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3cJ1IMl6d4bpPpYAD.IsQw--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2.cf.webp",
              "width": 900,
              "height": 625,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PlkanZFCHurVHg.4Kx4ifw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-amgen-inc-140003182.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-heavily-search-amgen-inc-140003182.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]